Post-liver transplant leptin results in resolution of severe recurrence of lipodystrophy-associated nonalcoholic steatohepatitis

American Journal of Transplantation

Volumn 13, Issue 11, 2013, Pages 3031-3034

  Casey, S P ^a   Lokan, J ^a   Testro, A ^a   Farquharson, S ^b   Connelly, A ^b   Proietto, J ^c   Angus, P W ^a  

^a AUSTIN HEALTH   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Leptin; lipodystrophy; liver transplantation; nonalcoholic steatohepatitis

Indexed keywords

METRELEPTIN;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LIPODYSTROPHY; LIVER BIOPSY; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT RESPONSE;

LEPTIN; LIPODYSTROPHY; LIVER TRANSPLANTATION; NONALCOHOLIC STEATOHEPATITIS;

ADULT; FATTY LIVER; FEMALE; HUMANS; LEPTIN; LIPODYSTROPHY; LIVER TRANSPLANTATION; MAGNETIC RESONANCE SPECTROSCOPY; POSTOPERATIVE COMPLICATIONS; RECURRENCE; TREATMENT OUTCOME;

EID: 84886801675     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12436     Document Type: Article

References (21)

1. Garg A., Lipodystrophies. Am J Med 2000; 108: 143-152.
2. Garg A, Misra A., Lipodystrophies causing metabolic syndrome. Endocrinol Metab Clin North Am 2004; 33: 305-331.
3. Misra A, Garg A., Clinical features and metabolic derangements in acquired generalized lipodystrophy: Case reports and review of the literature. Medicine 2000; 82: 129-146.
4. Klein S, Jahoor F, Wolfe RR, Stuart CA., Generalized lipodystrophy: In vivo evidence for hypermetabolism and insulin-resistant lipid, glucose, and amino acid kinetics. Metabolism 1992; 41: 893-896.
5. Cauble MS, Gilroy R, Sorrell MF, et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 2001; 71: 892-895.
6. Zhang F, Basinski MB, Beals JM, et al. Crystal structure of the obese protein leptin-E100. Nature 1997; 387: 206-209.
7. Haque WA, Shimomura I, Matsuzawa Y, Garg A., Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002; 87: 2395-2398.
8. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570-578.
9. Simha V, Szczepaniak LS, Wagner A, DePaoli A, Garg A., Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 2003; 26: 30-35.
10. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 1345-1350.
11. Zadeh ES, Lungu AO, Cochran EK, et al. The liver diseases of lipodystrophy: The long-term effect of leptin treatment. J Hepatol 2013; 59: 131-137.
12. Javor ED, Ghany MG, Cochran EK, et al. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005; 41: 753-760.
13. Moitra J, Mason MM, Olive M, et al. Life without white fat: A transgenic mouse. Genes Dev 1998; 12: 3168-3181.
14. Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: Model for congenital generalized lipodystrophy. Genes Dev 1998; 12: 3182-3194.
15. Gavrilova A, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105: 271-278.
16. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL., Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-76.
17. McNally M, Mannon RB, Javor D, et al. Successful renal transplantation in a patient with congenital generalized lipodystrophy. Am J Transplant 2004; 4: 447-449.
18. McDuffie JR, Riggs PA, Calis KA, et al. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab 2004; 89: 4258-4263.
19. Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. Endocr Pract 2011; 17: 922-932.
20. Reeder SB, Cruite I, Hamilton G, Sirlin CB., Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 2011; 34: 729-749.
21. Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51: 433-445.